Here are four takeaways:
1. KPI will develop topical biologic Kv1.3 inhibitors that target the immune cells which cause these autoimmune diseases.
2. KPI is also currently conducting research in lupus and chronic pain.
3. The two research programs, KPI-150 and KPI-190 are already underway.
4. KPI Therapeutics is a clinical-stage biotechnology company which develops first-in-class therapies for unmet medical needs in autoimmunity and chronic pain.
More articles on healthcare:
Nueterra divides into 2 companies: 4 highlights
15 statistics on physician investment mistakes
7 things to ASC leaders to know for Monday — Feb. 8, 2016
